TrialESMO open2026

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.

O O Babatunde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.